EyeGate files to initiate Ocular Bandage Gel pilot study

EyeGate Pharmaceuticals has filed a protocol with the FDA to initiate a pilot study of its Ocular Bandage Gel eye drop for the treatment of punctate epitheliopathies, the company announced in a press release.

The FDA will take 30 days to review the filing and then will allow the study to start or provide comments to be addressed, the release said.

“This is potentially a large opportunity, as OBG would be the only eye drop treatment available for the millions of patients in the U.S. with [punctate epitheliopathies] and tear film instability,” EyeGate CEO Stephen From said in the release. “We continue to explore new uses for our [hyaluronic acid] polymer and believe that its unique cross-linked capabilities will better serve patients who suffer from ocular surface pathologies and corneal injuries.”

EyeGate Pharmaceuticals has filed a protocol with the FDA to initiate a pilot study of its Ocular Bandage Gel eye drop for the treatment of punctate epitheliopathies, the company announced in a press release.

The FDA will take 30 days to review the filing and then will allow the study to start or provide comments to be addressed, the release said.

“This is potentially a large opportunity, as OBG would be the only eye drop treatment available for the millions of patients in the U.S. with [punctate epitheliopathies] and tear film instability,” EyeGate CEO Stephen From said in the release. “We continue to explore new uses for our [hyaluronic acid] polymer and believe that its unique cross-linked capabilities will better serve patients who suffer from ocular surface pathologies and corneal injuries.”